Armata Pharmaceuticals completes enrollment of Phase 1b/2a diSArm study
The Fly

Armata Pharmaceuticals completes enrollment of Phase 1b/2a diSArm study

Armata Pharmaceuticals (ARMP) announced that it has achieved full enrollment of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App